Robin Foa

Robin Foa is a senior European hematologist with extensive experience in CLL and acute lymphoblastic leukemia. He has contributed to clinical trials in CLL including the GIMEMA group studies and has investigated molecular remission and MRD monitoring as endpoints. For ALL, he pioneered the use of TKI-based combinations replacing chemotherapy in BCR-ABL positive ALL. His contributions to understanding leukemia biology and translating biological insights into therapy span multiple decades. He has received honorary memberships and awards from major international hematology societies.